The Centers for Medicare & Medicaid Services today repealed a final rule codifying how it defines “reasonable and necessary” coverage for items and services furnished under Medicare Parts A and B, as proposed in September. Scheduled to take effect Dec. 15, the rule also provided an expedited Medicare coverage pathway for certain innovative medical devices designated as breakthrough by the Food and Drug Administration, which CMS said may not have provided sufficient safety protections.  

CMS instead plans to work with the Food and Drug Administration, Agency for Healthcare Research and Quality, medical device makers and other stakeholders to develop an expeditious process to cover innovative devices for Medicare patients, and to hold at least two public meetings in 2022 to inform such policymaking.

In comments submitted on the proposed rule last November, AHA strongly opposed the elevation of definitional guideposts from a manual provision to enforceable standards in the Code of Federal Regulations, especially without a comprehensive assessment of the impact of that change and a clearer articulation of the process by which the new standard would be imposed.

 

Headline
The AHA Aug. 31 joined a coalition led by LeadingAge and other national healthcare organizations in submitting comments to the Centers for Medicare &…
Headline
The AHA Aug. 28 shared concerns with the Centers for Medicare & Medicaid Services regarding the calendar year 2027 hospital outpatient prospective payment…
Headline
The AHA provided comments to the Centers for Medicare & Medicaid Services Aug. 28 on its calendar year 2027 home health prospective payment system proposed…
Headline
The AHA Aug. 25 submitted comments to Sen. Bill Cassidy, R-La., on the 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act),…
Headline
The Department of Homeland Security today released a proposed rule to establish a new $103,265 filing fee for H-1B visa petitions that are subject to statutory…
Headline
President Trump announced Aug. 19 that he has nominated Heidi Overton to serve as the next commissioner of the Food and Drug Administration. Overton currently…